The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...
In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...
FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 ...
Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...
Morning Overview on MSN
Study links common blood pressure drug to improved cancer immunotherapy
Researchers have found that amlodipine, a calcium-channel blocker prescribed to tens of millions of people for high blood ...
In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results